AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1

AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1

No trades
See on Supercharts

Key facts today


AbbVie shares reached a record high after securing a patent extension for Rinvoq until 2037, blocking U.S. generics. Rinvoq generated $5.97 billion in 2024, vital for AbbVie's revenue.
BMO Capital has increased its price target for AbbVie (ABBV) to $240.00 per share, up from $215.00, while Wells Fargo has raised its target to $260.00 per share, up from $240.00.
Analyze the impactAnalyze the impact
Market capitalization
‪557.35 T‬ARS
2,175ARS
‪3.88 T‬ARS
‪51.58 T‬ARS
Beta (1Y)
0.03

About AbbVie Inc.


CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
ISIN
ARBCOM4603M9
FIGI
BBG00ZL7CCS3
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Check out other big names from the same industry as ABBV.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
ABBV5082874
AbbVie Inc. 4.55% 15-MAR-2035
Yield to maturity
Maturity date
Mar 15, 2035
ABBV5759202
AbbVie Inc. 4.95% 15-MAR-2031
Yield to maturity
Maturity date
Mar 15, 2031
ABBV5068388
AbbVie Inc. 4.625% 01-OCT-2042
Yield to maturity
Maturity date
Oct 1, 2042
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
Maturity date
Oct 1, 2042
ABBV4998675
AbbVie Inc. 4.75% 15-MAR-2045
Yield to maturity
Maturity date
Mar 15, 2045
ABBV5759204
AbbVie Inc. 5.35% 15-MAR-2044
Yield to maturity
Maturity date
Mar 15, 2044
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044
Yield to maturity
Maturity date
Jun 15, 2044
ABBV5006799
AbbVie Inc. 4.85% 15-JUN-2044
Yield to maturity
Maturity date
Jun 15, 2044
ABBV5068387
AbbVie Inc. 4.25% 21-NOV-2049
Yield to maturity
Maturity date
Nov 21, 2049
A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
Maturity date
Mar 15, 2045
A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
Maturity date
Jun 15, 2044

See all ABBV bonds